Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite. This article is currently FREE to read and share without paying.
The National Institutes of Health provided a non-recommendation for the use of ivermectin in COVID-19, stating that there was:
“insufficient evidence … to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
The process for reaching that non-recommendation, however, is opaque. The Panel members responsible for therapy recommendations are disclosed and also that:
“… working groups propose updates to the Guidelines based on the latest published research findings and evolving clinical information.”
However, NIH has gone to extreme efforts to avoid stating whether a vote was held to endorse the ivermectin non-recommendation. This includes fighting a Freedom of Information Act request in federal court. A deceptive non-vote would constitute an atrocity. NIH has also been secretive about the composition of the working group that proposed the ivermectin non-recommendation. The names of those individuals were redacted by the NIH from a&nbs...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).